ResMed (NYSE:RMD – Get Free Report) posted its quarterly earnings results on Thursday. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17, Briefing.com reports. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $1.64 EPS.
ResMed Stock Up 7.1 %
NYSE:RMD opened at $256.07 on Friday. The stock has a 50-day simple moving average of $240.22 and a 200 day simple moving average of $217.35. ResMed has a 52-week low of $132.24 and a 52-week high of $260.49. The company has a market cap of $37.58 billion, a PE ratio of 36.95, a PEG ratio of 1.94 and a beta of 0.69. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59.
ResMed Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.83%. ResMed’s dividend payout ratio (DPR) is 30.59%.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on ResMed
Insider Buying and Selling at ResMed
In other news, insider Kaushik Ghoshal sold 4,260 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $238.48, for a total transaction of $1,015,924.80. Following the completion of the transaction, the insider now directly owns 21,788 shares of the company’s stock, valued at $5,196,002.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $212.16, for a total transaction of $212,160.00. Following the sale, the chief financial officer now owns 89,056 shares in the company, valued at approximately $18,894,120.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kaushik Ghoshal sold 4,260 shares of the stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $238.48, for a total value of $1,015,924.80. Following the transaction, the insider now directly owns 21,788 shares of the company’s stock, valued at $5,196,002.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 123,874 shares of company stock worth $28,151,142. Corporate insiders own 0.71% of the company’s stock.
About ResMed
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Articles
- Five stocks we like better than ResMed
- Consumer Staples Stocks, Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Stock Market Upgrades: What Are They?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.